Valirx (VAL)

 

VAL Share PerformanceMore

52 week high7.7100 20/12/17
52 week low0.9000 15/11/17
52 week change 0.4500 (17.65%)
4 week volume140,266,875 28/03/18
price3.0000
price date1524500706
close3.1250

Media for (VAL)

Presenter: Oliver de Giorgio-Miller
10/04/2018
Presenter: Dr George Morris
06/02/2018

Latest NewsMore

ValiRx (VAL): 2017: a pivotal year

Hardman & Co Research Hardman & Co Research: ValiRx (VAL): 2017: a pivotal year 20-Apr-2018 / 10:43 GMT/BST Hardman & Co Research: 2017: a pivotal year ValiRx (VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company's two leading assets are in clinical trials: VAL201 (Phase I/...

FTSE gains momentum on upbeat corporate news

The FTSE 100 enjoyed modest gains amid a raft of mostly positive corporate news, trading 0.1% higher at 7,327 around mid...

GENEICE & VAL101 Update

RNS Number: 3747L ValiRx PLC 19 April 2018 ValiRx Plc ("ValiRx" or the "Company") GENEICE & VAL101 UPDATE "Positive results from VAL101 shown to be effective in inducing apoptosis (programmed cell death) in cancer cell models" London, UK ., 19 April 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to announce posit...

Notice of AGM

RNS Number: 6465K ValiRx PLC 12 April 2018 ValiRx Plc ("ValiRx" or the "Company") Posting of Annual Report and Accounts & Notice of Annual General Meeting London, UK, 12 April 2018: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medic...

ValiRx losses narrow on lower R&D costs

Cancer therapy developer ValiRx said annual losses narrowed following a reduction in R&D costs and administrative expe...

Final Results

RNS Number: 3252K ValiRx PLC 10 April 2018 VALIRX PLC ("ValiRx", "the Company" or "the Group") FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2017 London, UK, 10 April 2018: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision ...

ValiRx - Final Results

ValiRx granted US patent for therapeutic anti-cancer compound

ValiRx said it had been granted a patent in the US for its lead therapeutic compound for treating cancer, which was in cli...

Fundamental DataMore

EPS-8.54
Dividend yield0 %

Latest discussion posts More

  • Re: 4p options and other musings

    thanks for sharing your views and supporting arguement. Agreed...we are woefully undervalued. 3 weeks is a long time on aim. As we are so heavily reliant on small pi's, it ...
    20-Apr-2018
    fredd1eboy
  • is LSE down...?

    Can 't get on any board on LSE but can still get on to other sites..is it ...
    19-Apr-2018
    dickie3times
  • 4p options and other musings

    Dear all I guess today?s huge trading volume would have finally seen shot of YA (assuming they had any shares left to sell, as once they went below the 3% radar we would never ...
    19-Apr-2018
    drjekyllandmrhyde

Users' HoldingsMore

Users who hold Valirx also hold..

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL